Vir Biotechnology (VIR) Research & Development (2018 - 2026)
Vir Biotechnology recorded quarterly Research & Development of $108.9 million in Q1 2026, up 23.29% quarter-over-quarter from $88.3 million in Q4 2025, and down 8.2% year-over-year from $118.6 million in Q1 2025.
Vir Biotechnology's Research & Development history runs 9 years deep, the most recent figure standing at $108.9 million for Q1 2026.
- In Q1 2026, Research & Development fell 8.2% year-over-year to $108.9 million; the TTM figure through Mar 2026 stood at $446.2 million (down 15.0% YoY), while the FY2025 annual figure was $456.0 million, down 9.98% from the prior year.
- Research & Development came in at $108.9 million for Q1 2026 at Vir Biotechnology, up from $88.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $195.2 million in Q3 2024 to a low of $88.3 million in Q4 2025.
- A 5-year average of $125.0 million and a median of $114.2 million in 2022 frame the typical range for Research & Development.
- Across the five-year window, Research & Development soared 74.72% in 2023 and plunged 37.46% in 2024, its largest moves.
- Vir Biotechnology's Research & Development stood at $155.2 million in 2022, then dropped by 29.78% to $109.0 million in 2023, then retreated by 2.65% to $106.1 million in 2024, then decreased by 16.72% to $88.3 million in 2025, then rose by 23.29% to $108.9 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $108.9 million, $88.3 million, and $151.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | 108.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 108.92 Mn |
| Dec 31, 2025 | 88.35 Mn |
| Sep 30, 2025 | 151.46 Mn |
| Jun 30, 2025 | 97.51 Mn |
| Mar 31, 2025 | 118.65 Mn |
| Dec 31, 2024 | 106.08 Mn |
| Sep 30, 2024 | 195.18 Mn |
| Jun 30, 2024 | 105.11 Mn |
| Mar 31, 2024 | 100.13 Mn |
| Dec 31, 2023 | 108.97 Mn |
| Sep 30, 2023 | 145.03 Mn |
| Jun 30, 2023 | 168.08 Mn |
| Mar 31, 2023 | 157.64 Mn |
| Dec 31, 2022 | 155.17 Mn |
| Sep 30, 2022 | 114.17 Mn |
| Jun 30, 2022 | 115.08 Mn |
| Mar 31, 2022 | 90.23 Mn |
| Dec 31, 2021 | 128.34 Mn |
| Sep 30, 2021 | 98.67 Mn |
| Jun 30, 2021 | 86.13 Mn |
| Mar 31, 2021 | 134.87 Mn |
| Dec 31, 2020 | 87.10 Mn |
| Sep 30, 2020 | 70.68 Mn |
| Jun 30, 2020 | 79.65 Mn |
| Mar 31, 2020 | 64.98 Mn |
| Dec 31, 2019 | 52.93 Mn |
| Sep 30, 2019 | 39.86 Mn |
| Jun 30, 2019 | 29.81 Mn |
| Mar 31, 2019 | 25.87 Mn |
| Dec 31, 2018 | 21.97 Mn |
| Sep 30, 2018 | 29.84 Mn |